Pretreatment PET staging tied to better survival in SCLC

  • Hong JC & al.
  • J Natl Compr Canc Netw
  • 1 Feb 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pretreatment positron emission tomography (PET) staging was associated with significantly better OS and lung cancer-specific survival (LCSS) in patients with small-cell lung cancer (SCLC).

Why this matters

  • Current guidelines recommend PET/CT for patients with limited-stage SCLC (LS-SCLC) but not extensive-stage (ES-SCLC).

Study design

  • 10,135 patients from the Department of Veterans Affairs Central Cancer Registry diagnosed with SCLC between 2001 and 2010.
  • Funding: None disclosed.

Key results

  • 3510 patients had LS-SCLC, 6143 had ES-SCLC, and 482 had an unknown stage.
  • Median OS increased during the study period overall (6.2 vs 7.9 months; P<.0001 in ls-sclc vs months p=".004)," and es-sclc>
  • Median LCSS also improved overall (7.5 vs 8.6 months; P<.0001 in ls-sclc vs months p and es-sclc>
  • Pretreatment PET increased from 1.1% in 2001 to 39.2% in 2010, with the greatest increase in LS-SCLC (1.8% to 53.7%).
  • Pretreatment PET was independently associated with better OS and LCSS in LS-SCLC (HR, 0.78; 95% CI, 0.68-0.90 and HR, 0.74; 95% CI, 0.63-0.87) and ES-SCLC (HR, 0.69; 95% CI, 0.64-0.75 and HR, 0.70; 95% CI, 0.64-0.76).

Limitations

  • All-veteran population.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit